SCHEMBL26239736

SCHEMBL26239736

CC(C)CCN(Cc1ccncc1)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 2/20 0.41
▸ CYP1A2 P05177 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ FNTA P49354 2/20 0.33
▸ FNTB P49356 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ LOXL2 Q9Y4K0 1/20 0.33
▸ AAK1 Q2M2I8 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24968790 0.85 CYP19A1 (0.39) CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL13995625 0.81 SIGMAR1 (0.47) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL26239734 0.80 CHRNB2 (0.53) KDM4ELMNAALDH1A1HTTNPSR1
SCHEMBL10240740 0.79 HSD17B10 (0.41) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL23792418 0.79 NR1D1 (0.45) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL26239805 0.79 OPRK1 (0.41) KDM4EALDH1A1
SCHEMBL13995346 0.77 ALDH1A1 (0.43) CYP19A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL27000039 0.72 MAOB (0.45) CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL26724521 0.72 HTT (0.43) CYP19A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL23374745 0.72 KDM4E (0.43) CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 CYP19A1 4125/4885CYP1A2 4834/4885CYP3A4 4553/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 CYP19A1 4125/4885CYP1A2 4834/4885CYP3A4 4553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback